TuHURA reports Q2 2026 results, outlines second-half milestones for AML and MCC programs

TuHURA Biosciences reported financial results for the quarter ended June 30, 2026, alongside a corporate update dated August 14, 2026.

The company said it filed an Investigational New Drug application to evaluate its VISTA inhibiting antibody, TBS-2025, in molecularly defined subsets of AML and other blood related cancers.¹ TuHURA said the filing is aligned with guidance the FDA previously gave on developing the drug both as monotherapy and in combination with menin inhibitors for AML, and that the FDA said its planned IND meeting would not be needed, instead providing written responses on the proposed Phase 1b/2 plan.¹

Looking ahead, TuHURA said it expects to receive safe-to-proceed feedback from FDA and initiate its Phase 1b/2 trial of VISTA in mutNPM1 relapsed/refractory AML in the second half of 2026, along with starting in vivo proof-of-concept studies for its MDSC inhibitor bispecific ADCs, and potentially receiving orphan drug designation in Merkel cell carcinoma for IFx-2.0 and in AML for TBS-2025.¹ For IFx-2.0, the company listed further targets including preliminary results in the first half of 2027 from an IR study of IFx-2.0 with Keytruda for deep seated MCC, and completion of enrollment in the Phase 3 study of IFx-2.0 in the second half of 2027.¹

On financing, TuHURA said it announced a $50 million credit facility and royalty transaction in April 2026 that extends its anticipated cash runway into 2028.¹ The company said the facility carries a 12% annual interest rate with monthly interest payments and principal due at a five-year maturity on April 21, 2031, and was provided by TuHURA's largest shareholder.¹ CEO James Bianco said the facility provides a non-convertible source of operating capital with what he called adequate runway to achieve the company's strategic objectives.¹ TuHURA reported cash and cash equivalents of $1.0 million at June 30, 2026.¹